Dr. Reddy’s Developed, Made and Filed the Rituximab. Fresenius Only Sells It.
- The FDA approved a rituximab biosimilar to Rituxan, developed, manufactured and submitted by Dr. Reddy’s Laboratories. Under an exclusive commercialisation agreement, Fresenius Kabi holds exclusive rights to commercialise it in the United States.
- Rituximab is a CD20-directed cytolytic antibody that depletes B cells through several immune-mediated mechanisms. Approved US adult indications straddle two franchises: non-Hodgkin lymphoma and chronic lymphocytic leukaemia in oncology, plus rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis in immunology. A boxed warning covers fatal infusion-related reactions, severe mucocutaneous reactions, HBV reactivation and progressive multifocal leukoencephalopathy.
- Approval rested on a totality of the evidence approach spanning analytical, non-clinical, pharmacokinetic and clinical data showing high similarity and no clinically meaningful differences from the reference product.
- Fresenius calls biopharma a core pillar of its strategy and describes building a vertically integrated, end-to-end business from research and development through manufacturing to global commercialisation. The release names no brand, no interchangeability designation and no launch date.
Access read
The strategy statement and the transaction contradict each other inside one press release. Fresenius describes building a vertically integrated biopharma business running from research through manufacturing to commercialisation. This product was developed, manufactured and filed by Dr. Reddy’s. Fresenius is the channel and nothing else. That is not a failure, it is the correct answer for this molecule. Rituximab biosimilars have been competing in the United States since 2019 and the price has been ground down accordingly. Nobody builds capacity for a late entrant into an eroded market. The industrial margin on this molecule left for India some time ago, and what remains in the US is contracting.
- Read the omissions, they are the most informative part. No brand name, no interchangeability designation, no launch date. For a provider-administered intravenous biologic that is the correct set of things to leave out, because interchangeability governs substitution at the pharmacy counter and rituximab never passes one. It moves through buy and bill under Part B, where the decisions belong to group purchasing and integrated-network contracting, to average sales price arithmetic, and to the 340B spread. Interchangeability is close to irrelevant here. The J-code and the contract are the entire commercial question.
- What Fresenius actually acquired is a second call point on a single molecule. Rituximab spans oncology and immunology, so one approval gives both a haematology-oncology field force and a rheumatology field force something to carry, and Fresenius already sells a tocilizumab biosimilar into rheumatology. That is the strategic complement the release names, and it is a better reason to hold this licence than any margin on the vials. Judge the deal on pull-through across two franchises rather than on unit economics in either one.
- What to watch: the average sales price trajectory after launch, because a late entrant into a mature biosimilar market usually accelerates erosion rather than taking share at the prevailing price, and erosion decides whether this licence ever pays. Then watch the rest of the portfolio for contrast. Fresenius announced FDA and EMA acceptance of a vedolizumab biosimilar candidate last week and named no third-party developer, where this release credits Dr. Reddy’s in the first line. The gap between how those two are disclosed is where you will read whether end to end is a strategy or a slogan.